•
Dec 31, 2021

Adtalem Q2 2022 Earnings Report

Adtalem's results for Q2 2022, which ended December 31, 2021, were announced, revealing a revenue increase driven by the Walden acquisition, alongside a pending sale of the Financial Services segment and continued COVID-19 headwinds.

Key Takeaways

Adtalem Global Education reported a 58.4% increase in revenue to $371.2 million compared to the prior year, driven by the acquisition of Walden. Diluted earnings per share were $0.36, while operating income was $24.7 million. The company announced the pending sale of its Financial Services segment and revised its full-year guidance.

Revenue increased 58.4% year-over-year to $371.2 million due to the Walden acquisition.

Diluted earnings per share were reported at $0.36, compared to $0.44 in the prior year.

Operating income was $24.7 million, down from $29.1 million in the prior year.

Adtalem revised its full-year guidance due to the pending sale of the Financial Services segment and continued COVID-19 headwinds.

Total Revenue
$371M
Previous year: $283M
+31.1%
EPS
$0.75
Previous year: $0.77
-2.6%
New Students
7.92K
Previous year: 3.85K
+105.5%
Total Students
80.26K
Previous year: 40.24K
+99.5%
Gross Profit
$191M
Previous year: $156M
+22.1%
Cash and Equivalents
$275M
Previous year: $449M
-38.7%
Free Cash Flow
-$47.9M
Previous year: -$23.9M
+100.0%
Total Assets
$3.66B
Previous year: $2.27B
+60.9%

Adtalem

Adtalem

Forward Guidance

Adtalem revised its full fiscal year 2022 guidance for adjusted revenue, excluding special items, to be within the range of $1,350 million and $1,390 million, and adjusted diluted earnings per share of $2.90 to $3.10 from continuing operations, excluding special items.

Positive Outlook

  • Focus as a pure play, leading provider of talent to the healthcare industry
  • Strategic partnership with Society of Teachers of Family Medicine
  • Pending sale of Financial Services segment thereby moving it to discontinued operations.
  • Synergies of the recent Walden acquisition
  • Re-accreditation for American University of the Caribbean School of Medicine

Challenges Ahead

  • Impact of COVID-related headwinds associated with the Omicron variant that has further burdened healthcare professionals, which continues to negatively impact enrollments
  • Decrease in new student enrollment was primarily attributable to COVID-related headwinds in Chamberlain’s post-licensure programs.
  • Segment operating loss was $2.4 million, driven primarily by intangible amortization expense for Walden.
  • Second quarter segment revenue decreased 2.0% to $139.1 million compared with the prior year for Chamberlain
  • Diluted earnings per share was $0.36 compared with diluted earnings per share of $0.44 in the prior year